By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is neutral to bearish on Eli Lilly's $9 billion debt issuance, with concerns about high leverage, competition, and potential regulatory hurdles for Centessa's sleep apnea candidate outweighing the benefits of diversifying into new pipelines through acquisitions.
Risk: High leverage and potential regulatory issues with Centessa's sleep apnea candidate
Opportunity: Diversification into new pipelines through acquisitions
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following a credit rating upgrade by S&P Global Ratings and a favorable market environment.
The sale consisted of eight tranches with maturities spanning 2 to 40 years, with the longest-term bonds yielding 0.8 percentage points above Treasuries. The proceeds are earmarked for general corporate purposes and the financing of two major deals totaling nearly $15 billion: the $7.8 billion acquisition of sleep-drug producer Centessa Pharmaceuticals Plc and the $7 billion purchase of cancer-drug developer Kelonia Therapeutics.
Notably, the terms include a provision where Eli Lilly and Company (NYSE:LLY) must repurchase certain notes at 101 cents on the dollar if the Centessa transaction fails to close. This capital raise follows a strong first-quarter performance and increased 2026 guidance driven by high demand for the company’s weight-loss medications.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Eli Lilly is currently priced for flawless execution, meaning any deviation from their aggressive growth trajectory in the GLP-1 market will likely trigger a sharp valuation contraction."
Eli Lilly’s $9 billion debt issuance is a classic aggressive expansion play, signaling management’s confidence in Zepbound and Mounjaro cash flows to cover the interest expense. By locking in long-term debt now, they are effectively betting that their R&D pipeline—specifically the recent acquisitions of Kelonia and Centessa—will generate returns far exceeding the cost of capital. However, the market is pricing LLY for perfection, trading at an astronomical forward P/E ratio exceeding 50x. While the growth narrative is compelling, the stock is highly sensitive to any regulatory shifts in Medicare drug pricing or supply chain bottlenecks that could slow the rollout of their GLP-1 blockbusters.
If supply constraints persist or if new entrants like Viking Therapeutics or Amgen successfully bring oral GLP-1s to market, LLY’s massive debt load could become a significant drag on earnings per share during a period of slowing growth.
"LLY's debt-financed M&A bets amplify execution risks overlooked in the article's rosy 15-year outlook."
Eli Lilly's record $9B bond issuance, upsized amid S&P upgrade and strong demand (tight 0.8% spreads over Treasuries on 40-year tranche), funds $15B acquisitions of Centessa (sleep apnea) and Kelonia (cancer), diversifying from blockbuster weight-loss drugs that boosted Q1 and 2026 guidance. This signals market confidence in LLY's pipeline. However, the repurchase clause at 101% if Centessa fails underscores deal risk, while ballooning debt raises leverage concerns in a high-rate world. Article downplays fierce obesity competition from Novo Nordisk (NVO) and prior manufacturing bottlenecks for GLP-1s, plus unproven acquisition payoffs in biotech's high failure rate.
Against neutrality, the bull case shines if GLP-1 cash flows explode to service debt effortlessly, with Centessa/Kelonia yielding new hits to sustain 15-year dominance beyond crowded weight-loss.
"LLY's bond raise reflects operational strength, but the acquisitions are a high-stakes bet on obesity/oncology dominance in a market where competitive intensity is already eroding pricing power."
LLY's $9B bond raise at favorable terms (40-year tranche at ~2.8% yield) signals confidence, but the article conflates capital-raising discipline with a 15-year buy thesis without evidence. The real story: LLY is deploying $15B into two acquisitions (Centessa, Kelonia) betting on weight-loss and oncology pipelines. Q1 guidance beat is real, but GLP-1 competition is intensifying—Novo Nordisk (NVO), Viking Therapeutics (VKIN), and generics will compress margins. The 101-cent repurchase clause on Centessa notes is a red flag: it signals deal risk the article downplays. LLY's valuation already prices in obesity dominance.
If Centessa or Kelonia fail to deliver pipeline value, LLY carries $15B in acquisition debt on a balance sheet that will face margin pressure as GLP-1 becomes commoditized within 5-7 years. The article's 15-year horizon assumes no competitive disruption.
"LLY's 15-year bull case hinges on successful megadeals and Tirzepatide-driven growth, but the added leverage and potential payer/regulatory headwinds could derail near-term returns."
LLY looks set to ride momentum from weight-loss drugs and a capital raise that funds two sizable acquisitions. Yet the article glosses over meaningful risks: the two deals total ~$15B against a mature pharma giant’s balance sheet, creating leverage that raises interest costs and reduces flexibility if rates rise or cash flow slows. The Centessa/Kelonia closings hinge on regulatory and integration success; a failure or delay would trigger the 101-on-dollar repurchase clause and cap downside. Absent durable revenue from Tirzepatide and reliable payer coverage, the stock’s long bull-case depends on execution more than growth signals.
Even if the deals close, the extra leverage may depress ROIC and raise financing risk; if tirzepatide momentum stalls or payer dynamics worsen, debt service becomes a strain.
"The M&A activity signals a exhaustion of internal R&D efficiency rather than a strategic expansion of the pipeline."
Claude and Grok are fixating on the 101% repurchase clause as a 'red flag,' but they are misinterpreting standard M&A contingency architecture. This is a common defensive hedge for bondholders, not a signal of internal deal failure. The real risk isn't the clause; it's the opportunity cost. By levering up for mid-stage biotech, LLY is signaling they have exhausted internal R&D efficiency. They are buying growth because their own pipeline velocity is hitting a ceiling.
"LLY's internal pipeline is not exhausted, but added leverage amplifies acquisition execution risks amid intensifying competition."
Gemini rightly downplays the repurchase clause, but overstates R&D exhaustion—LLY's internal pipeline (e.g., orforglipron oral GLP-1 Phase 3, reteplase stroke drug) remains robust, per latest 10-Q. Unflagged risk: $9B debt pushes gross leverage to ~2.5x EBITDA (est. post-deal), vulnerable if Centessa's sleep apnea candidate faces FDA scrutiny like prior GLP-1 orals. Competition erodes moat faster than acquisitions build it.
"LLY's leverage is manageable only if both GLP-1 cash flows hold AND acquisitions succeed—a two-variable bet the market is pricing as near-certain."
Grok's 2.5x gross leverage estimate needs stress-testing. If Centessa's sleep apnea program hits FDA headwinds—plausible given prior GLP-1 cardiac signals—LLY faces simultaneous margin compression from GLP-1 commoditization AND acquisition write-down risk. That's not a sequential risk; it's correlated. The panel hasn't priced in a scenario where both Mounjaro pricing power AND Centessa clinical success deteriorate within 18 months. Debt service becomes acute, not theoretical.
"Long-dated debt creates a maturity/refinancing risk that could crowd out R&D and capex if growth slows."
Claude, the overlooked risk isn’t a red flag from the 101% repurchase clause—it's the 40-year debt maturity. Locking in ~2.8% on a long tranche when you’re funding $15B of mid-stage acquisitions means a massive refinancing and amortization curve down the line. If GLP-1 momentum stalls or Centessa/Kelonia underperform, debt service could eclipse R&D spend and capex, truncating optionality just as the strong growth narrative relies on it.
The panel is neutral to bearish on Eli Lilly's $9 billion debt issuance, with concerns about high leverage, competition, and potential regulatory hurdles for Centessa's sleep apnea candidate outweighing the benefits of diversifying into new pipelines through acquisitions.
Diversification into new pipelines through acquisitions
High leverage and potential regulatory issues with Centessa's sleep apnea candidate